Hepamerz (L-Ornithine L-Aspartate - Lola)

# Hepamerz (L-Ornithine L-Aspartate - Lola) ## Overview L-Ornithine L-Aspartate (LOLA) is a stable salt of two amino acids. It serves as a substrate for the urea cycle and glutamine synthesis, assisting in the detoxification of ammonia in the liver and skeletal muscle. It is utilized primarily for the management of hyperammonemia in liver disease. ## Primary Indications * Management of hepatic encephalopathy (HE). * Treatment of hyperammonemia associated with acute or chronic liver disease (e.g., cirrhosis, fatty liver). ## Adult Dosing * **Oral (Granules):** 5 g to 10 g (one to two sachets) three times daily, taken with meals. * **Intravenous (Infusion):** 20 g to 40 g per day, administered via continuous infusion (dissolved in 500 mL of an infusion solution like 5% glucose or saline). * **Maximum Dose:** Do not exceed 40 g per day via IV infusion to avoid administration rate-related complications. ## Pediatric Dosing * **Safety/Efficacy:** Well-established pediatric dosing is limited. Clinical use in children is generally off-label and based on individual institutional protocols. Consult local pediatric hepatology guidelines for specific weight-based dosing if necessary. ## Dose Adjustments * **Renal Impairment:** Use caution. Monitor serum creatinine and BUN closely. In severe renal failure (CrCl < 30 mL/min), accumulation of amino acids may occur; dose reduction is often required. * **Hepatic Impairment:** No dose reduction required for liver disease, as it is the primary target of the therapy. ## Contraindications * Hypersensitivity to L-Ornithine or L-Aspartate. * Severe renal insufficiency (typically defined as serum creatinine > 3 mg/dL). ## Adverse Effects * **Gastrointestinal:** Nausea, vomiting, abdominal pain, diarrhea, and flatulence. * **Systemic:** Muscle pain or joint pain (arthralgia). * **IV-specific:** Injection site reactions or irritation if the infusion rate is too rapid. ## Key Drug Interactions * There are no major clinically significant drug-drug interactions documented. However, it should be used cautiously with other hepatotoxic medications. ## Monitoring * **Ammonia Levels:** Monitor blood ammonia levels to assess treatment efficacy. * **Renal Function:** Serum creatinine and BUN, especially in patients with existing renal compromise. * **Liver Function Tests (LFTs):** Periodic assessment of hepatic status. ## Clinical Pearls * **Administration:** Oral granules should be dissolved in a large glass of liquid (e.g., water, tea, or juice). * **IV Safety:** When administering IV, do not exceed an infusion rate of 5 g per hour to prevent nausea and vomiting. * **Place in Therapy:** LOLA is often used as an adjunct to lactulose or rifaximin in the management of HE, though it does not replace the gold standard of ammonia reduction via osmotic laxatives. * **Stability:** If using IV infusions, monitor the solution for clarity and ensure it is freshly prepared. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical practices vary by region and institution. Always verify current prescribing information, local clinical guidelines, and patient-specific factors with the official product monograph or a qualified healthcare provider before prescribing or administering medication.